• Skip to main content
  • Skip to primary sidebar
  • Home
  • News
  • Education
  • Events
  • Interviews
    • Career spotlight
  • Opinion
    • Professional Dilemmas
    • Patient perspective
  • PIPcast
  • Jobs
  • Business Directory

Pharmacy in Practice

EDX/20/1154
Date of prep: December 2020

Prescribing information and
adverse events reporting

For healthcare professionals only

Clinicians urged to accelerate COVID-19 research recruitment

5th April 2020 by PIP editor Leave a Comment

 

The Chief Medical Officers of all four nations of the UK and Professor Stephen Powis have written to the Medical Directors and the Directors of Pharmacy in Scotland to ask that every effort is made to enrol COVID-19 patients in the national priority clinical trials.

 

This move marks the acceleration of the research phase of the government strategy to address the COVID-19 threat. The UK Government has said that the research phase is aimed at achieving the following objectives:

 

  • Better understanding the virus and the actions that will lessen its effect on the UK population.
  • Innovate responses including diagnostics, drugs and vaccines.
  • Use the evidence to inform the development of the most effective models of care.

 

There are currently trials in primary care, hospital settings and intensive care units.

 

The key three national trials are:

 

  • PRINCIPLE (higher-risk patients in primary care trial).
  • RECOVERY (in-hospital trial).
  • REMAP-CAP (critically ill patient trial).

 

Other priority studies, including observational studies, are listed here.

 

Urging clinicians to support the recruitment of patients to these trials the group commented:

 

“These trials are being run as simply as they can to reduce the burden on the NHS, with adaptive designs so further treatments can be added if new promising candidates are identified. The results are essential to the future treatment of UK and global patients.

 

“We will ensure important results are disseminated rapidly to improve practice. The faster that patients are recruited, the sooner we will get reliable results.

 

“While it is for every individual clinician to make prescribing decisions, we strongly discourage the use of off-licence treatments outside of a trial, where participation in a trial is possible. Use of treatments outside of a trial, where participation was possible, is a wasted opportunity to create information that will benefit others.

 

“The evidence will be used to inform treatment decisions and benefit patients in the immediate future.

 

“Any treatment given for coronavirus other than general supportive care, treatment for underlying conditions, and antibiotics for secondary bacterial complications, should currently be as part of a trial, where that is possible.”

 

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

Download [332.59 KB]

 

 

This circular is being shared under the Open Government Copyright licence.

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Related

Next article  Covid-19 community pharmacy vaccine campaign begins

Filed Under: COVID-19, News, Scotland Tagged With: Coronavirus, PIP news, research

Register for our upcoming webinar and live Q&A

About PIP editor

Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.

Reader Interactions

Begin the discussion right here Cancel reply

Primary Sidebar

Categories

Follow Us

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Twitter

PIP business directory

Letters to the editor

Letters to the editor

Is there a pragmatic way through the provisional registration problem?

‘PRN’ medicines like Tramadol should never be on repeat

I failed by one mark and now can’t register as a pharmacist

Community pharmacy isn’t set up to deliver interventions at scale

More letters to the editor here...

Blogs

💊 PIP live pharmacy blog

Winter stresses must not ‘destabilise’ general practice

What is it like to depend on medicine to treat endometriosis?

Opinion

Why is pharmacy not integral to government mass vaccination plans?

Pharmacy Covid-19 vaccination involvement is a ‘no-brainer’

The great patient medication returns debacle

CPD Challenges

💊 CPD Challenge: How well do you understand pulmonary embolisms?

💊 CPD Challenge: Prescribing and dispensing clozapine

💊 CPD Challenge: Oral anticoagulants – Dabigatran

More CPD challenges here...

© 2021 · About Pharmacy In Practice · Site mantained by Mike

This site is for healthcare professionals, please confirm you are a healthcare professional to continue.

YES

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Pharmacy In Practice uses cookies, by continuing to use this site we will assume you are ok with that Find out more.